Dissecting the role of TGF-beta type I receptor/ALK5 in pancreatic ductal adenocarcinoma: Smad activation is crucial for both the tumor suppressive and prometastatic function

Oncogene

Volumn 26, Issue 33, 2007, Pages 4850-4862

  Schniewind, B ^a   Groth, S ^a   Sebens Muerkoster S ^b   Sipos, B ^c   Schafer H ^b   Kalthoff, H ^a   Fandrich F ^a   Ungefroren, H ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b Laboratory of Molecular Gastroenterology and Hepatology   (Germany)

^c University Hospital Kiel ^*  (Germany)

Author keywords

ALK5; Metastasis; Pancreatic carcinoma; Smad; TGF

Indexed keywords

SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CARCINOGENICITY; CELL PROLIFERATION; CLONE; CONTROLLED STUDY; EPITHELIUM CELL; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER METASTASIS; MESENCHYME CELL; MOUSE; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REPORTER GENE; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; UPREGULATION;

ACTIVIN RECEPTORS, TYPE I; ADENOCARCINOMA; ANIMALS; CARCINOMA, PANCREATIC DUCTAL; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOBLOTTING; MICE; MICE, SCID; MUTATION; NEOPLASM METASTASIS; NEOPLASMS, EXPERIMENTAL; PANCREATIC NEOPLASMS; PHOSPHORYLATION; PROTEIN BINDING; RATS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SMAD PROTEINS; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA; TUMOR BURDEN;

MUS;

EID: 34447637421     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210272     Document Type: Article

References (56)

1. Baldwin RL, Friess H, Yokoyama M, Lopez ME, Kobrin MS, Buchler MW et al. (1996). Attenuated ALK5 receptor expression in human pancreatic cancer: correlation with resistance to growth inhibition. Int J Cancer 67: 283-288.
2. Bornstein P. (2001). Thrombospondins as matricellular modulators of cell function. J Clin Invest 107: 929-934.
3. Böttinger EP, Jakubczak JL, Haines DC, Bagnall K, Wakefield LM. (1997). Transgenic mice overexpressing a dominant-negative mutant type II transforming growth factor beta receptor show enhanced tumorigenesis in the mammary gland and lung in response to the carcinogen 7,12-dimethylbenz-[a]-anthracene. Cancer Res 57: 5564-5570.
4. Boyer Arnold N, Korc M. (2005). Smad7 abrogates transforming growth factor-beta1-mediated growth inhibition in COLO-357 cells through functional inactivation of the retinoblastoma protein. J Biol Chem 280: 21858-21866.
5. Chen WB, Lenschow W, Tiede K, Fischer JW, Kalthoff H, Ungefroren H. (2002). Smad4/DPC4-dependent regulation of biglycan gene expression by transforming growth factor-beta in pancreatic tumor cells. J Biol Chem 277: 36118-36128.
6. Claassen GF, Hann SR. (2000). A role for transcriptional repression of p21CIP1 by c-Myc in overcoming transforming growth factor beta-induced cell-cycle arrest. Proc Natl Acad Sci USA 97: 9498-9503.
7. Dai JL, Turnacioglu KK, Schutte M, Sugar AY, Kern SE. (1998). Dpc4 transcriptional activation and dysfunction in cancer cells. Cancer Res 58: 4592-4597.
8. Deckers M, van Dinther M, Buijs J, Que I, Lowik C, van der Pluijm G et al. (2006). The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. Cancer Res 66: 2202-2209.
9. Derynck R, Akhurst RJ, Balmain A. (2001). TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 29: 117-129.
10. Derynck R, Zhang YE. (2003). Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425: 577-584.
11. Duda DG, Sunamura M, Lefter LP, Furukawa T, Yokoyama T, Yatsuoka T et al. (2003). Restoration of SMAD4 by gene therapy reverses the invasive phenotype in pancreatic adenocarcinoma cells. Oncogene 22: 6857-6864.
12. Ellenrieder V, Hendler SF, Boeck W, Seufferlein T, Menke A, Ruhland C et al. (2001b). Transforming growth factor beta1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation. Cancer Res 61: 4222-4228.
13. Ellenrieder V, Hendler SF, Ruhland C, Boeck W, Adler G, Gress TM. (2001a). TGF-beta-induced invasiveness of pancreatic cancer cells is mediated by matrix metalloproteinase-2 and the urokinase plasminogen activator system. Int J Cancer 93: 204-211.
14. Fensterer H, Giehl K, Buchholz M, Ellenrieder V, Buck A, Kestler HA et al. (2004). Expression profiling of the influence of RAS mutants on the TGFB1-induced phenotype of the pancreatic cancer cell line PANC-1. Genes Chromosomes Cancer 39: 224-235.
15. Franzén P, ten Dijke P, Ichijo H, Yamashita H, Schulz P, Heldin CH et al. (1993). Cloning of a TGF beta type I receptor that forms a heteromeric complex with the TGF beta type II receptor. Cell 75: 681-692.
16. Frederick JP, Liberati NT, Waddell DS, Shi Y, Wang XF. (2004). Transforming growth factor beta-mediated transcriptional repression of c-myc is dependent on direct binding of Smad3 to a novel repressive Smad binding element. Mol Cell Biol 24: 2546-2559.
17. Freeman JW, Mattingly CA, Strodel WE. (1995). Increased tumorigenicity in the human pancreatic cell line MIA PaCa-2 is associated with an aberrant regulation of an IGF-1 autocrine loop and lack of expression of the TGF-beta type RII receptor. J Cell Physiol 165: 155-163.
18. Friess H, Yamanaka Y, Buchler M, Berger HG, Kobrin MS, Baldwin RL et al. (1993a). Enhanced expression of the type II transforming growth factor beta receptor in human pancreatic cancer cells without alteration of type III receptor expression. Cancer Res 53: 2704-2707.
19. Friess H, Yamanaka Y, Buchler M, Ebert M, Beger HG, Gold LI et al. (1993b). Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology 105: 1846-1856.
20. Giehl K, Seidel B, Gierschik P, Adler G, Menke A. (2000). TGFbeta1 represses proliferation of pancreatic carcinoma cells which correlates with Smad4-independent inhibition of ERK activation. Oncogene 19: 4531-4541.
21. Goggins M, Shekher M, Turnacioglu K, Yeo CJ, Hruban RH, Kern SE. (1998). Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas. Cancer Res 58: 5329-5332.
22. Grau AM, Zhang L, Wang W, Ruan S, Evans DB, Abbruzzese JL et al. (1997). Induction of p21waf1 expression and growth inhibition by transforming growth factor beta involve the tumor suppressor gene DPC4 in human pancreatic adenocarcinoma cells. Cancer Res 57: 3929-3934.
23. Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E et al. (1996). DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271: 350-353.
24. Iglesias M, Frontelo P, Gamallo C, Quintanilla M. (2000). Blockade of Smad4 in transformed keratinocytes containing a Ras oncogene leads to hyperactivation of the Ras-dependent Erk signalling pathway associated with progression to undifferentiated carcinomas. Oncogene 19: 4134-4145.
25. Janda E, Lehmann K, Killisch I, Jechlinger M, Herzig M, Downward J et al. (2002). Ras and TGF[beta] cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways. J Cell Biol 156: 299-313.
26. Javelaud D, Mauviel A. (2005). Crosstalk mechanisms between the mitogen-activated protein kinase pathways and Smad signaling downstream of TGF-beta: implications for carcinogenesis. Oncogene 24: 5742-5750.
27. Kang Y. (2006). Pro-metastasis function of TGFbeta mediated by the Smad pathway. J Cell Biochem 98: 1380-1390.
28. Kang Y, He W, Tulley S, Gupta GP, Serganova I, Chen CR et al. (2005). Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci USA 102: 13909-13914.
29. Kleeff J, Ishiwata T, Maruyama H, Friess H, Truong P, Buchler MW et al. (1999). The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer. Oncogene 18: 5363-5372.
30. Kuang C, Xiao Y, Liu X, Stringfield TM, Zhang S, Wang Z et al. (2006). In vivo disruption of TGF-beta signaling by Smad7 leads to premalignant ductal lesions in the pancreas. Proc Natl Acad Sci USA 103: 1858-1863.
31. Lawler J. (2000). The functions of thrombospondin-1 and-2. Curr Opin Cell Biol 12: 634-640.
32. Levy L, Hill CS. (2005). Smad4 dependency defines two classes of. Mol Cell Biol 25: 8108-8125.
33. Massagué J. (1998). TGF-beta signal transduction. Annu Rev Biochem 67: 753-791.
34. Massagué J, Blain SW, Lo RS. (2000). TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 103: 295-309.
35. Moustakas A, Pardali K, Gaal A, Heldin CH. (2002). Mechanisms of TGF-beta signaling in regulation of cell growth and differentiation. Immunol Lett 82: 85-91.
36. Muraoka-Cook RS, Dumont N, Arteaga CL. (2005a). Dual role of transforming growth factor beta in mammary tumorigenesis and metastatic progression. Clin Cancer Res 11: 937s-943s.
37. Muraoka-Cook RS, Shin I, Yi JY, Easterly E, Barcellos-Hoff MH, Yingling JM et al. (2005b). Activated type I TGFbeta receptor kinase enhances the survival of mammary epithelial cells and accelerates tumor progression. Oncogene 25: 3408-3423.
38. Nakagawa T, Li JH, Garcia G, Mu W, Piek E, Bottinger EP et al. (2004). TGF-beta induces proangiogenic and anti-angiogenic factors via parallel but distinct Smad pathways. Kidney Int 66: 605-613.
39. Nicolas FJ, Hill CS. (2003). Attenuation of the TGF-beta-Smad signaling pathway in pancreatic tumor cells confers resistance to TGF-beta-induced growth arrest. Oncogene 22: 3698-3711.
40. Oft M, Akhurst RJ, Balmain A. (2002). Metastasis is driven by sequential elevation of H-ras and Smad2 levels. Nat Cell Biol 4: 487-494.
41. Oft M, Peli J, Rudaz C, Schwarz H, Beug H, Reichmann E. (1996). TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev 10: 2462-2477.
42. Peinado H, Ballestar E, Esteller M, Cano A. (2004). Snail mediates E-cadherin repression by the recruitment of the Sin3A/histone deacetylase 1 (HDAC1)/HDAC2 complex. Mol Cell Biol 24: 306-319.
43. Peng B, Fleming JB, Breslin T, Grau AM, Fojioka S, Abbruzzese JL et al. (2002). Suppression of tumorigenesis and induction of p15(ink4b) by Smad4/DPC4 in human pancreatic cancer cells. Clin Cancer Res 8: 3628-3638.
44. Reiss M, Barcellos-Hoff MH. (1997). Transforming growth factor-beta in breast cancer: a working hypothesis. Breast Cancer Res Treat 45: 81-95.
45. Rowland-Goldsmith MA, Maruyama H, Matsuda K, Idezawa T, Ralli M, Ralli S et al. (2002). Soluble type II transforming growth factor-beta receptor attenuates expression of metastasis-associated genes and suppresses pancreatic cancer cell metastasis. Mol Cancer Ther 1: 161-167.
46. Schwarte-Waldhoff I, Volpert OV, Bouck NP, Sipos B, Hahn SA, Klein-Scory S et al. (2000). Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis. Proc Natl Acad Sci USA 97: 9624-9629.
47. Siegel PM, Shu W, Cardiff RD, Muller WJ, Massagué J. (2003). Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc Natl Acad Sci USA 100: 8430-8435.
48. Tian F, Byfield SD, Parks WT, Stuelten CH, Nemani D, Zhang YE et al. (2004). Smad-binding defective mutant of transforming growth factor beta type I receptor enhances tumorigenesis but suppresses metastasis of breast cancer cell lines. Cancer Res 64: 4523-4530.
49. Ungefroren H, Groth S, Ruhnke M, Kalthoff H, Fändrich F. (2005). Transforming growth factor-beta (TGF-beta) type I receptor/ALK5-dependent activation of the GADD45beta gene mediates the induction of biglycan expression by TGF-beta. J Biol Chem 280: 2644-2652.
50. Ungefroren H, Schniewind B, Groth S, Chen WB, Sebens Müerköster S, Kalthoff H et al. (2007). Antitumor activity of ALK1 in pancreatic carcinoma cells. Int J Cancer [Epub ahead of print].
51. Voss M, Wolff B, Savitskaia N, Ungefroren H, Deppert W, Schmiegel W et al. (1999). TGFbeta-induced growth inhibition involves cell cycle inhibitor p21 and pRb independent from p15 expression. Int J Oncol 14: 93-101.
52. Warshaw AL, Fernandez-del Castillo C. (1992). Pancreatic carcinoma. N Engl J Med 326: 455-465.
53. Weidner N, Semple JP, Welch WR, Folkman J. (1991). Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 324: 1-8.
54. Wieser R, Wrana JL, Massaguè J. (1995). GS domain mutations that constitutively activate T beta R-I, the downstream signaling component in the TGF-beta receptor complex. EMBO J 14: 2199-2208.
55. Yu L, Hebert MC, Zhang YE. (2002). TGF-beta receptor-activated p38 MAP kinase mediates Smad-independent TGF-beta responses. EMBO J 21: 3749-3759.
56. Zavadil J, Böttinger EP. (2005). TGF-beta and epithelial- tomesenchymal transitions. Oncogene 24: 5764-5774.